U.S. Pankreaskrebs-Diagnostikmarktumfang, Größe & Zukünftiges Wachstum Bis 2030

Us Pancreatic Cancer Diagnostics Market

Marktgröße in Milliarden USD

CAGR : 8.30 %

Prognosezeitraum	2024 –2030
Marktgröße (Basisjahr)	MILLIONEN USD Anfrage
Marktgröße (Prognosejahr)	MILLIONEN USD Antrag auf Freischaltung
CAGR	8.30 %
Wichtige Marktteilnehmer	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Anfrage zur Freischaltung

>US-Markt für Bauchspeicheldrüsenkrebsdiagnostik nach Testtyp (Bildgebungstest, Biopsie, Bluttest, Genomtest und andere), Krebsstadium (Stadium 0, Stadium I, Stadium II, Stadium III und Stadium IV), Tumortyp (exokrine Tumoren und neuroendokrine Tumoren), Produkt (instrumentenbasierte Produkte, plattformbasierte Produkte, Kits und Reagenzien und andere Verbrauchsmaterialien), Technologie (Fluoreszenz-in-situ-Hybridisierung, Sequenzierung der nächsten Generation , Fluoroimmunoassay, vergleichende genomische Hybridisierung, Immunhistochemie und andere), Anwendung (Screening, Diagnostik und Vorhersage, Prognose und Forschung), Endbenutzer (Krankenhäuser, Diagnosezentren, Krebsforschungszentren, akademische Institute, ambulante chirurgische Zentren und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) – Branchentrends und Prognose bis 2030.

Marktanalyse und Einblicke zur Diagnostik von Bauchspeicheldrüsenkrebs in den USA

Die zunehmende Verbreitung von Bauchspeicheldrüsenkrebs sowie der steigende Bedarf an Diagnoseprodukten für diese Erkrankungen haben die Marktnachfrage erhöht. Der technologische Fortschritt zur einfachen Produktversorgung und schnelle Produktionsanlagen tragen ebenfalls zum Marktwachstum bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase stark auf Produkteinführungen und Produktzulassungen. Darüber hinaus unterstützen Regierung und Aufsichtsbehörden die Marktteilnehmer aufgrund der zunehmenden Zahl an neuen Produkten bei der Produktzulassung.

Der US-Markt für Bauchspeicheldrüsenkrebsdiagnostik dürfte im Prognosejahr aufgrund der Zunahme der Marktteilnehmer und der Verfügbarkeit fortschrittlicher Dienste wachsen. Darüber hinaus sind die Hersteller in Forschungs- und Entwicklungsaktivitäten involviert, um neue Dienste auf den Markt zu bringen. Die zunehmende Forschung im Bereich der Leukämiediagnose und -entwicklung dürfte das Marktwachstum weiter ankurbeln.

Es wird jedoch erwartet, dass Schwierigkeiten bei Leukämie-Screening-Techniken das Marktwachstum im Prognosezeitraum bremsen werden. Steigende Gesundheitsausgaben für Krebsdiagnose und -behandlung werden dem Markt voraussichtlich Möglichkeiten bieten, die Behandlung zu verbessern. Das verbesserte Bewusstsein für regelmäßige Gesundheitsuntersuchungen, neue Diagnosezentren und Fortschritte bei Diagnosemethoden für Bauchspeicheldrüsenkrebs sowie technologische Entwicklungen werden voraussichtlich das Marktwachstum ankurbeln. Die hohen Testkosten und strengen Vorschriften und Standards für die Zulassung und Vermarktung von Krebsdiagnoseprodukten und -instrumenten werden jedoch voraussichtlich das Marktwachstum bremsen.

Der US-Markt für Bauchspeicheldrüsenkrebsdiagnostik ist unterstützend und zielt darauf ab, die Krankheit einzudämmen und so die Genesung und Leistungsfähigkeit der Betroffenen zu verbessern. Data Bridge Market Research analysiert, dass der US-Markt für Bauchspeicheldrüsenkrebsdiagnostik im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate von 8,3 % wachsen wird.

Berichtsmetrik	Details
Prognosezeitraum	2023 bis 2030
Basisjahr	2022
Historische Jahre	2021 (Anpassbar auf 2020 – 2015)
Quantitative Einheiten	Umsatz in Millionen USD und Preise in USD
Abgedeckte Segmente	Nach Testtyp (Bildgebungstest, Biopsie, Bluttest, Genomtest und andere), Krebsstadium (Stadium 0, Stadium I, Stadium II, Stadium III und Stadium IV), Tumortyp (Exokrine Tumoren und Neuroendokrine Tumoren), Produkt (Instrumentenbasierte Produkte, Plattformbasierte Produkte, Kits und Reagenzien und andere Verbrauchsmaterialien), Technologie (Fluoreszenz-In-situ-Hybridisierung, Sequenzierung der nächsten Generation, Fluoroimmunoassay, Vergleichende Genomische Hybridisierung, Immunhistochemie und andere), Anwendung (Screening, Diagnose und Vorhersage, Prognose und Forschung), Endbenutzer (Krankenhäuser, Diagnosezentren, Krebsforschungszentren, akademische Institute, ambulante chirurgische Zentren und andere), Vertriebskanal (Direktausschreibung, Einzelhandelsverkauf und andere)
Abgedeckte Regionen	Südliche USA, westliche USA, mittlerer Westen und nordöstliche USA
Abgedeckte Marktteilnehmer	Agilent Technologies, Inc., BD, Biological Dynamics, CANON MEDICAL SYSTEMS CORPORATION, ClearNote Health, CTK Biotech, Inc., Danaher., Exact Sciences Corporation, F. Hoffman-La Roche Ltd, FUJIFILM Holdings America Corporation, GRAIL, Immunovia, Koninklijke Philips NV, Laboratory Corporation of America Holdings, MP BIOMEDICALS, Myriad Genetics, Inc., QIAGEN, Quest Diagnostics Incorporated, Siemens Healthcare GmbH und Thermo Fisher Scientific Inc. unter anderem

Marktdefinition

Bauchspeicheldrüsenkrebs ist tödlich und der Diagnoseprozess von Bauchspeicheldrüsenkrebs ist auch mit Sicherheitsproblemen verbunden. Er ist nicht kosteneffizient. Eine der teuersten medizinischen Erkrankungen zur Behandlung von Krebs. Krebspatienten können ins Krankenhaus eingeliefert werden und erhalten eine Vielzahl von Therapien für Tumore, wie z. B. Operationen, Strahlenbehandlung und systemische Therapie. Die Krankenversicherungsprämien für Krebspatienten sind heute höher als in der Vergangenheit. Darüber hinaus steigen ihre Zuzahlungs-, Selbstbehalts- und Zuzahlungskosten. Die Diagnose von Bauchspeicheldrüsenkrebs umfasst Ultraschall, Biopsieverfahren und Bluttests. Bauchspeicheldrüsenkrebs ist eine der häufigsten Todesursachen weltweit und die Prävalenz dieser Krankheit hat besorgniserregend zugenommen. Der Krebs ist auf die oberen Schichten der Pankreasgangzellen beschränkt und hat tiefere Gewebe nicht befallen. Er hat sich nicht außerhalb der Bauchspeicheldrüse ausgebreitet. Diese Tumoren werden manchmal als Carcinoma in situ bezeichnet. Er hat sich nicht auf nahe gelegene Lymphknoten oder entfernte Stellen ausgebreitet.

Bauchspeicheldrüsenkrebs kann schwierig zu diagnostizieren sein, da er trotz seiner vielfältigen Anzeichen und Symptome unspezifisch ist und mit anderen, weiter verbreiteten Erkrankungen in Verbindung gebracht werden kann. Bauchspeicheldrüsenkrebs ist die achthäufigste Krebsart bei Frauen und die zehnthäufigste Krebsart bei Männern. Die Inzidenzraten von Bauchspeicheldrüsenkrebs steigen jedes Jahr um etwa 1 %. Er tritt seltener auf. Er kommt bei Frauen etwas häufiger vor als bei Männern, das durchschnittliche Lebenszeitrisiko, an Bauchspeicheldrüsenkrebs zu erkranken, beträgt bei beiden Geschlechtern jedoch im Durchschnitt etwa ½ von 1 %. Die hohen Kosten im Zusammenhang mit der Behandlung und dem Diagnoseverfahren dürften jedoch das Marktwachstum bremsen.

Marktdynamik für Bauchspeicheldrüsenkrebsdiagnostik in den USA

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Einschränkungen und Herausforderungen. All diese werden im Folgenden ausführlich erläutert:

TREIBER

Zunehmende Prävalenz von Bauchspeicheldrüsenkrebs

Diese Krebsart kann alle Altersgruppen betreffen. Bauchspeicheldrüsenkrebs kann schwierig zu diagnostizieren sein, da diese trotz der Vielzahl von Anzeichen und Symptomen unspezifisch sind und mit anderen, weiter verbreiteten Erkrankungen in Verbindung gebracht werden können. Bauchspeicheldrüsenkrebs ist die achthäufigste Krebsart bei Frauen und die zehnthäufigste Krebsart bei Männern. Die Inzidenzraten von Bauchspeicheldrüsenkrebs steigen jedes Jahr um etwa 1 %. Er tritt seltener auf. Er kommt bei Frauen etwas häufiger vor als bei Männern, das durchschnittliche Lebenszeitrisiko, an Bauchspeicheldrüsenkrebs zu erkranken, beträgt bei beiden Geschlechtern jedoch im Durchschnitt etwa ½ von 1 %. Zu diesen Erkrankungen gehören Bauchschmerzen, Appetitlosigkeit oder ungewollter Gewichtsverlust, Gelbfärbung der Haut und des Weißen der Augen (Gelbsucht), hell gefärbter Stuhl, dunkel gefärbter Urin und juckende Haut. Es ist die achthäufigste Krebsart, die bei Erwachsenen und Kindern diagnostiziert wird, die meisten Fälle treten jedoch bei Erwachsenen auf. Obwohl die Erkrankung in jedem Alter diagnostiziert werden kann, ist sie vor dem 45. Lebensjahr selten. Das durchschnittliche Diagnosealter liegt bei 68 Jahren. Aufgrund verschiedener Risikofaktoren ist die Häufigkeit von Bauchspeicheldrüsenkrebs zu einem bedeutenden sozioökonomischen Problem geworden. Dies dürfte als Treiber für das Marktwachstum wirken.

Neue technologische Fortschritte bei der Behandlung von Bauchspeicheldrüsenkrebs

Bauchspeicheldrüsenkrebs wird selten in einem frühen Stadium erkannt, wenn er noch am ehesten heilbar ist. Dies liegt daran, dass er oft erst dann Symptome verursacht, wenn er sich bereits auf andere Organe ausgebreitet hat. Spezialisten müssen Krebszellen und nicht krebsartige Zellen manuell diagnostizieren, indem sie Zellbilder unter dem Mikroskop untersuchen und Beschriftungen durch Anmerkungen anbringen. Diese manuelle mikroskopische Untersuchung ist jedoch zeitaufwändig und kann zu einer falschen Diagnose führen. Das Risiko, falsche Medikamente zu verschreiben, wurde dann durch den Einsatz computergestützter Software verringert. Die Entwicklung eines automatischen und zuverlässigen Klassifizierungssystems wurde unerlässlich, um die verheerenden Auswirkungen der Bauchspeicheldrüsenerkrankung zu stoppen. Mehrere Segmentierungstechniken bildeten die Grundlage der bestehenden Klassifizierungsalgorithmen für Bauchspeicheldrüsenkrebs.

Die manuelle Untersuchung gefärbter Blutausstriche mittels Mikroskopie, die derzeit zur Erstdiagnose von Bauchspeicheldrüsenkrebs verwendet wird, ist zeitaufwändig und fehleranfällig. Ein wirksames Instrument zur Unterstützung von Ärzten bei medizinischen Entscheidungen ist die auf Deep Learning basierende, menschenzentrierte biomedizinische Diagnostik. Es wurden verschiedene computergestützte Diagnosetechniken entwickelt, um Blutbilder automatisch zu erkennen. Fortschritte bei der Diagnose von Bauchspeicheldrüsenkrebs sind zu einer allgemein akzeptierten Technologie geworden, die qualitativ hochwertige Diagnosetests ermöglicht. Die Entwicklung mehrerer neuer Diagnosemethoden wird das Marktwachstum steigern, da viele neue und fortschrittliche Produkte auf den Markt kommen. Daher wird erwartet, dass auf dem Markt eine Nachfrage nach Produkten zur Diagnose von Bauchspeicheldrüsenkrebs entsteht.

GELEGENHEIT

Steigende Gesundheitsausgaben für Krebsdiagnose und -behandlung

Weltweit nehmen die F&E-Aktivitäten aufgrund der öffentlichen Gesundheitsausgaben und der wirtschaftlichen Leistung zu. Dabei steht die Gesundheitsbranche hinsichtlich der für das Gesundheitswesen ausgegebenen Summen an zweiter Stelle aller Branchen. Steigende Gesundheitsausgaben können zu einer besseren Bereitstellung von F&E-Möglichkeiten führen. Es wird erwartet, dass die Nachfrage nach Bauchspeicheldrüsenkrebsdiagnostik steigt. Steigende Gesundheitsausgaben für die Behandlung von Bauchspeicheldrüsenkrebs helfen dem Patienten auch, problemlos fortschrittliche Diagnostik und Behandlung für eine schnelle Genesung in Anspruch zu nehmen. Die Ausgaben für das Gesundheitswesen setzen sich aus einer Kombination aus Eigenzahlungen (Personen, die für ihre Behandlung zahlen), staatlichen Ausgaben und Quellen zusammen. Dazu gehören auch Krankenversicherungen und Aktivitäten von Nichtregierungsorganisationen. Diese steigenden Gesundheitsausgaben für die Krebsbehandlung werden voraussichtlich eine Chance für Marktwachstum darstellen.

Von nun an werden die steigenden Gesundheitsausgaben positiv mit der Produktentwicklung, Produktregistrierung und Produkteinführung in Verbindung gebracht. Daher wird erwartet, dass die steigenden Gesundheitsausgaben und die staatliche Unterstützung das Marktwachstum in den kommenden Jahren weiter vorantreiben werden. Der Anstieg der Gesundheitsausgaben wirkt sich auch auf die zunehmende Einführung fortschrittlicher Krebsdiagnoseprodukte und eine bessere Behandlung von Krebspatienten aus. Aus diesem Grund werden steigende Gesundheitsausgaben für die Behandlung von Bauchspeicheldrüsenkrebs voraussichtlich als Chance für Marktwachstum dienen.

ZURÜCKHALTUNG/HERAUSFORDERUNG

Späte Diagnose und schlechte Prognose von Bauchspeicheldrüsenkrebs

Die späte Diagnose der Krankheit ist auf die zunehmende Zahl von Bauchspeicheldrüsenkrebstumoren zurückzuführen, die auf häufig verwendete Krebstherapien nicht so gut reagieren wie andere, weniger tödliche Krebsarten. Es gibt jedoch Behandlungsmöglichkeiten, darunter Operation, Chemotherapie und Bestrahlung. Es gibt verschiedene Arten von Bauchspeicheldrüsenkrebs. Die meisten Bauchspeicheldrüsenkrebsarten sind exokrine Formen. Dies bedeutet, dass sie in Zellen entstehen, die Verdauungssäfte der Bauchspeicheldrüse produzieren. Etwa 30 % der Patienten sind Raucher und 5 % haben eine Vorgeschichte von Pankreatitis, einer Entzündung der Bauchspeicheldrüse, die durch Steine oder starken Alkoholkonsum verursacht werden kann.

Krebs ist weltweit die häufigste Todesursache. Bis 2030 wird mit 13,1 Millionen zusätzlichen krebsbedingten Todesfällen pro Jahr gerechnet. Bei frühzeitiger Diagnose und richtiger Behandlung können einige Krebsarten jedoch geheilt werden. Im Diagnoseprozess kann es zu Verzögerungen bei der Krebsdiagnose kommen. Wenn Patienten potenziell krebsartige Anzeichen übersehen oder nicht darauf reagieren, kann es zu Verzögerungen kommen. Der Hauptgrund für die verspätete Diagnose ist mangelndes öffentliches Wissen über frühe Anzeichen von Krebs, insbesondere wenn diese Symptome ungewöhnlich sind. Diese Faktoren führen häufig zu einer späten Diagnose, die eine schlechte Prognose zur Folge hat. Daher wird erwartet, dass diese Faktoren das Marktwachstum hemmen.

Auswirkungen von COVID-19 auf den US-Markt für Bauchspeicheldrüsenkrebsdiagnostik

COVID-19 hat sich negativ auf das Marktwachstum ausgewirkt, da Patienten mit Bauchspeicheldrüsenkrebs ihre Operation aufgrund eines rasanten Anstiegs der COVID-19-Fälle in allen Regionen verschoben haben. Darüber hinaus bestand bei Menschen mit Bauchspeicheldrüsenkrebs das Risiko, schwer zu erkranken. Die Angst vor einer Coronavirus-Infektion beeinträchtigte das Marktwachstum während der Pandemie.

Jüngste Entwicklungen

Im Dezember 2022 gab die FUJIFILM Holdings America Corporation bekannt, dass das Unternehmen einen Kaufvertrag mit Inspirata, Inc. zur Übernahme eines digitalen Pathologieunternehmens abgeschlossen hat, um sein robustes Enterprise-Imaging-Angebot zu erweitern. Dies ermöglicht die Integration von Pathologiebildern und -daten in das elektronische Patientenaktensystem einer Gesundheitsorganisation, um die Versorgung von Krebspatienten zu optimieren.
Im August 2020 gab die Siemens Healthcare GmbH bekannt, dass sie eine Vereinbarung mit Varian Medical Systems, Inc. geschlossen hat. Mit dieser Übernahme hat die Siemens Healthcare GmbH dazu beigetragen, fortschrittliche Lösungen zur Behandlung von Krebs zu entwickeln und ihre Position in der Gesundheitsbranche zu stärken.
Im Mai 2020 gab F. Hoffmann-La Roche Ltd. die Übernahme von Stratos Genomics bekannt. Mit dieser Übernahme wird sich das Unternehmen auch mit der Entwicklung von DNA-basierter Sequenzierung für diagnostische Zwecke befassen. Dies hat das Segment der Gesundheitsdiagnose des Unternehmens gestärkt und somit zu höheren Umsätzen für das Unternehmen geführt.

Umfang des US-Marktes für Bauchspeicheldrüsenkrebsdiagnostik

Der US-Markt für Bauchspeicheldrüsenkrebsdiagnostik ist in acht wichtige Segmente unterteilt, basierend auf Testtyp, Krebsstadium, Tumortyp, Produkt, Anwendung, Technologie, Endbenutzer und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktansprache sowie bei der Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.

Testtyp

Bildgebungstest
Biopsie
Blutprobe
Genomischer Test
Sonstiges

Auf der Grundlage des Testtyps ist der Markt in bildgebende Verfahren, Biopsie, Bluttests, Genomtests und andere unterteilt.

Krebsstadien

Etappe 0
Stufe I
Stufe II
Stufe III
Stadium IV

Auf der Grundlage der Krebsstadien ist der Markt in Stadium 0, Stadium I, Stadium II, Stadium III und Stadium IV segmentiert.

Tumortyp

Exokrine Tumoren
Neuroendokrine Tumoren

Auf der Grundlage des Tumortyps wird der Markt in exokrine Tumoren und neuroendokrine Tumoren segmentiert.

Produkt

Instrumentenbasierte Produkte
Plattformbasierte Produkte
Kits und Reagenzien
Andere Verbrauchsmaterialien

Auf Produktbasis ist der Markt in instrumentenbasierte Produkte, plattformbasierte Produkte, Kits und Reagenzien sowie andere Verbrauchsmaterialien segmentiert.

Anwendung

Vorsorgeuntersuchungen
Diagnostisch und prädiktiv
Prognose
Forschung

Auf der Grundlage der Anwendung ist der Markt in die Bereiche Screening, Diagnostik und Vorhersage, Prognose und Forschung segmentiert.

Technologie

Fluoreszenz-In-Situ-Hybridisierung
Sequenzierung der nächsten Generation
Fluorimmunoassay
Vergleichende genomische Hybridisierung
Immunhistochemisch
Sonstiges

Auf der Grundlage der Technologie ist der Markt in Fluoreszenz-in-situ-Hybridisierung, Sequenzierung der nächsten Generation, Fluoroimmunoassay, vergleichende genomische Hybridisierung, Immunhistochemie und andere unterteilt.

Endbenutzer

Krankenhäuser
Diagnostikzentren
Krebsforschungszentren
Akademische Institute
Ambulante Chirurgische Zentren
Sonstiges

Auf der Grundlage des Endbenutzers ist der Markt in Krankenhäuser, Diagnosezentren, Krebsforschungszentren, akademische Institute, ambulante chirurgische Zentren und andere segmentiert.

Vertriebskanal

Direkte Ausschreibung
Einzelhandelsumsätze
Sonstiges

Auf der Grundlage des Vertriebskanals wird der Markt in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges segmentiert.

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Länderanalyse/Einblicke

Der US-Markt für Bauchspeicheldrüsenkrebsdiagnostik wird analysiert und Erkenntnisse und Trends zur Marktgröße werden nach Testtyp, Krebsstadium, Tumorart, Produkt, Anwendung, Technologie, Endbenutzer und Vertriebskanal wie oben angegeben bereitgestellt.

Die vom Markt abgedeckten Regionen sind der Süden der USA, der Westen der USA, der Mittlere Westen der USA und der Nordosten der USA

Der Markt für Bauchspeicheldrüsenkrebsdiagnostik im Süden der USA dürfte aufgrund der steigenden Prävalenz und Inzidenz von Bauchspeicheldrüsenkrebs und des gestiegenen Bewusstseins für die Bauchspeicheldrüsenkrebsdiagnostik wachsen. Dies sind die wichtigsten Faktoren, die das Marktwachstum im Land ankurbeln dürften.

Der regionale Abschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie die Analyse der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung einer Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit von US-Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.

Wettbewerbsumfeld und Analyse der Marktanteile für Bauchspeicheldrüsenkrebsdiagnostik in den USA

Das Wettbewerbsumfeld auf dem US-Markt für Bauchspeicheldrüsenkrebsdiagnostik liefert Einzelheiten zu den Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz in den USA, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf dem Markt.

Zu den wichtigsten Marktteilnehmern auf dem US-Markt für Bauchspeicheldrüsenkrebsdiagnostik zählen unter anderem Agilent Technologies, Inc., BD, Biological Dynamics, CANON MEDICAL SYSTEMS CORPORATION, ClearNote Health, CTK Biotech, Inc., Danaher., Exact Sciences Corporation, F. Hoffman-La Roche Ltd, FUJIFILM Holdings America Corporation, GRAIL, Immunovia, Koninklijke Philips NV, Laboratory Corporation of America Holdings, MP BIOMEDICALS, Myriad Genetics, Inc., QIAGEN, Quest Diagnostics Incorporated, Siemens Healthcare GmbH und Thermo Fisher Scientific Inc.

SKU-69962

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 U.S. CHRONIC PANCREATITIS TESTING MARKET

4.1 CHRONIC PANCREATITIS

4.2 LABORATORY TESTING

4.3 CHRONIC PANCREATITIS DIAGNOSE

4.4 PANCREATIC FUNCTION TESTS

4.4.1 INDIRECT PANCREATIC FUNCTION TESTS

4.4.2 DIRECT PANCREATIC FUNCTION TESTS

5 PREMIUM INSIGHTS

5.1 PESTEL MODEL

5.2 PORTER'S FIVE FORCES

5.3 EPIDEMIOLOGY

6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS

7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 GROWTH IN THE PREVALENCE OF PANCREATIC CANCER

8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS

8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER

8.2 RESTRAINTS

8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS

8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER

8.3 OPPORTUNITIES

8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER

8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS

8.4 CHALLENGES

8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES

8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

9 IMPACT OF COVID-19

9.1 OVERVIEW

9.2 DEMAND SURGE FOR MEDICAL DIAGNOSTIC

9.3 GROWTH IN GOVERNMENT SPENDING ON HEALTHCARE

9.4 STRATEGIC INITIATIVES BY KEY PLAYERS

9.5 INCREASE IN THE PRICE OF TESTS KITS AND REAGENTS

10 OUTLOOK AND TREND OF THE MARKET AFTER COVID -19

11 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE

11.1 OVERVIEW

11.2 IMAGING TEST

11.2.1 COMPUTED TOMOGRAPHY (CT) SCAN

11.2.2 MAGNETIC RESONANCE IMAGING (MRI)

11.2.3 MR CHOLANGIOPANCREATOGRAPHY

11.2.4 MR ANGIOGRAPHY (MRA)

11.3 ULTRASOUND

11.3.1 ABDOMINAL ULTRASOUND

11.3.2 ENDOSCOPIC ULTRASOUND (EUS)

11.4 CHOLANGIOPANCREATOGRAPHY

11.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP)

11.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)

11.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC)

11.5 POSITRON EMISSION TOMOHRAPHY (PET)

11.6 OTHERS

11.7 BIOPSY

11.8 CT-GUIDED NEEDLE BIOPSY

11.9 FINE NEEDLE ASPIRATION (FNA)

11.1 CORE NEEDLE BIOPSY

11.11 OTHERS

11.12 BLOOD TEST

11.13 LIVER FUNCTION TEST

11.14 TUMOR MARKER

11.14.1 CA 19-9 BIOMARKER TEST

11.14.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST

11.14.3 CA 50 MARKER TEST

11.14.4 OTHERS

11.15 OTHERS

11.16 GENOMIC TEST

11.17 OTHERS

12 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES

12.1 OVERVIEW

12.2 STAGE IV

12.3 STAGE III

12.4 STAGE II

12.4.1 STAGE IIA

12.4.2 STAGE IIB

12.5 STAGE I

12.5.1 STAGE IB

12.5.2 STAGE IA

12.6 STAGE 0

13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE

13.1 OVERVIEW

13.2 EXOCRINE TUMORS

13.2.1 INSTRUMENT-BASED PRODUCTS

13.2.2 PLATFORM-BASED PRODUCTS

13.2.3 KITS AND REAGENTS

13.2.4 OTHER CONSUMABLES

13.3 NEUROENDOCRINE TUMORS

13.3.1 INSTRUMENT-BASED PRODUCTS

13.3.2 PLATFORM-BASED PRODUCTS

13.3.3 KITS AND REAGENTS

13.3.4 OTHER CONSUMABLES

14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT

14.1 OVERVIEW

14.2 INSTRUMENT-BASED PRODUCTS

14.2.1 IMAGING

14.2.2 BIOPSY

14.3 PLATFORM-BASED PRODUCTS

14.3.1 NEXT-GENERATION SEQUENCING

14.3.2 MICROARRAYS

14.3.3 PCR

14.3.4 OTHERS

14.4 KITS AND REAGENTS

14.4.1 CA19-9 PANCREATIC CANCER TEST KITS

14.4.1.1 ELISA TEST KITS

14.4.1.2 CASETTE TEST KITS

14.4.1.3 OTHERS

14.4.2 CEA PANCREATIC CANCER TEST KITS

14.4.2.1 ELISA TEST KITS

14.4.2.2 CASETTE TEST KITS

14.4.2.3 OTHERS

14.5 OTHERS

15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

15.1 OVERVIEW

15.2 FLUORESCENT IN SITU HYBRIDIZATION

15.3 NEXT GENERATION SEQUENCING

15.4 FLUORIMMUNOASSAY

15.5 COMPARATIVE GENOMIC HYBRIDIZATION

15.6 IMMUNOHISTOCHEMICAL

15.7 OTHERS

16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION

16.1 OVERVIEW

16.2 SCREENING

16.2.1 INSTRUMENT-BASED PRODUCTS

16.2.2 PLATFORM-BASED PRODUCTS

16.2.3 KITS AND REAGENTS

16.2.4 OTHER CONSUMABLES

16.3 DIAGNOSTIC AND PREDICTIVE

16.3.1 INSTRUMENT-BASED PRODUCTS

16.3.2 PLATFORM-BASED PRODUCTS

16.3.3 KITS AND REAGENTS

16.3.4 OTHER CONSUMABLES

16.4 PROGNOSTIC

16.4.1 INSTRUMENT-BASED PRODUCTS

16.4.2 PLATFORM-BASED PRODUCTS

16.4.3 KITS AND REAGENTS

16.4.4 OTHER CONSUMABLES

16.5 RESEARCH

16.5.1 INSTRUMENT-BASED PRODUCTS

16.5.2 PLATFORM-BASED PRODUCTS

16.5.3 KITS AND REAGENTS

16.5.4 OTHER CONSUMABLES

17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER

17.1 OVERVIEW

17.2 HOSPITALS

17.3 DIAGNOSTIC CENTERS

17.4 CANCER RESEARCH CENTERS

17.5 ACADEMIC INSTITUTES

17.6 AMBULATORY SURGICAL CENTERS

17.7 OTHERS

18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 DIRECT TENDER

18.3 RETAIL SALES

18.4 OTHERS

19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION

19.1 OVERVIEW

19.2 U.S.

19.3 SOUTHERN U.S.

19.3.1 FLORIDA

19.3.2 TEXAS

19.3.3 NORTH CAROLINA

19.3.4 GEORGIA

19.3.5 VIRGINIA

19.3.6 TENNESSEE

19.3.7 REST OF SOUTHERN U.S.

19.4 WESTERN U.S.

19.4.1 ILLINOIS

19.4.2 OHIO

19.4.3 MICHIGAN

19.4.4 INDIANA

19.4.5 MISSOURI

19.4.6 MINNESOTA

19.4.7 REST OF WESTERN U.S.

19.5 MID-WESTERN U.S.

19.5.1 CALIFORNIA

19.5.2 WASHINGTON

19.5.3 ARIZONA

19.5.4 COLORADO

19.5.5 OREGON

19.5.6 NEVADA

19.5.7 REST OF MID-WESTERN U.S.

19.6 NORTH-EASTERN U.S.

19.6.1 NEW YORK

19.6.2 PENNSYLVANIA

19.6.3 NEW JERSEY

19.6.4 MASSACHUSETTS

19.6.5 MARYLAND

19.6.6 CONNECTICUT

19.6.7 REST OF NORTH-EASTERN U.S.

20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: EUROPE

21 SWOT ANALYSIS

22 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET

22.1 F. HOFFMANN- LA ROCHE LTD

22.1.1 COMPANY SNAPSHOT

22.1.2 SWOT

22.1.3 REVENUE ANALYSIS

22.1.4 PRODUCT PORTFOLIO

22.1.5 RECENT DEVELOPMENT

22.2 KONINKLIJKE PHILIPS N.V.

22.2.1 COMPANY SNAPSHOT

22.2.2 REVENUE ANALYSIS

22.2.3 PRODUCT PORTFOLIO

22.2.4 RECENT DEVELOPMENTS

22.3 CANON MEDICAL SYSTEMS CORPORATION

22.3.1 COMPANY SNAPSHOT

22.3.2 REVENUE ANALYSIS

22.3.3 PRODUCT PORTFOLIO

22.3.4 RECENT DEVELOPMENT

22.4 GRAIL

22.4.1 COMPANY PROFILE

22.4.2 PRODUCT PORTFOLIO

22.4.3 RECENT DEVELOPMENT

22.5 SIEMENS HEALTHCARE GMBH

22.5.1 COMPANY SNAPSHOT

22.5.2 REVENUE ANALYSIS

22.5.3 PRODUCT PORTFOLIO

22.5.4 RECENT DEVELOPMENT

22.6 AGILENT TECHNOLOGIES, INC.

22.6.1 COMPANY PROFILE

22.6.2 REVENUE ANALYSIS

22.6.3 PRODUCT PORTFOLIO

22.6.4 RECENT DEVELOPMENT

22.7 BIOLOGICAL DYNAMICS

22.7.1 COMPANY SNAPSHOT

22.7.2 SWOT

22.7.3 PRODUCT PORTFOLIO

22.7.4 RECENT DEVELOPMENTS

22.8 BD

22.8.1 COMPANY SNAPSHOT

22.8.2 REVENUE ANALYSIS

22.8.3 PRODUCT PORTFOLIO

22.8.4 RECENT DEVELOPMENT

22.9 CLEARNOTE HEALTH

22.9.1 COMPANY SNAPSHOT

22.9.2 SWOT

22.9.3 PRODUCT PORTFOLIO

22.9.4 RECENT DEVELOPMENT

22.1 CTK BIOTECH, INC.

22.10.1 COMPANY PROFILE

22.10.2 PRODUCT PORTFOLIO

22.10.3 RECENT DEVELOPMENT

22.11 DANAHER.

22.11.1 COMPANY SNAPSHOT

22.11.2 SWOT

22.11.3 REVENUE ANALYSIS

22.11.4 PRODUCT PORTFOLIO

22.11.5 RECENT DEVELOPMENTS

22.12 EXACT SCIENCES CORPORATION

22.12.1 COMPANY SNAPSHOT

22.12.2 SWOT

22.12.3 REVENUE ANALYSIS

22.12.4 PRODUCT PORTFOLIO

22.12.5 RECENT DEVELOPMENT

22.13 FUJIFILM HOLDINGS AMERICA CORPORATION

22.13.1 COMPANY SNAPSHOT

22.13.2 REVENUE ANALYSIS

22.13.3 PRODUCT PORTFOLIO

22.13.4 RECENT DEVELOPMENT

22.14 IMMUNOVIA

22.14.1 COMPANY SNAPSHOT

22.14.2 SWOT

22.14.3 REVENUE ANALYSIS

22.14.4 PRODUCT PORTFOLIO

22.14.5 RECENT DEVELOPMENT

22.15 LABORATORY CORPORATION OF AMERICA HOLDINGS

22.15.1 COMPANY SNAPSHOT

22.15.2 REVENUE ANALYSIS

22.15.3 PRODUCT PORTFOLIO

22.15.4 RECENT DEVELOPMENTS

22.16 MP BIOMEDICALS.

22.16.1 COMPANY PROFILE

22.16.2 PRODUCT PORTFOLIO

22.16.3 RECENT DEVELOPMENT

22.17 MYRIAD GENETICS, INC.

22.17.1 COMPANY SNAPSHOT

22.17.2 REVENUE ANALYSIS

22.17.3 PRODUCT PORTFOLIO

22.17.4 RECENT DEVELOPMENT

22.18 QIAGEN

22.18.1 COMPANY SNAPSHOT

22.18.2 REVENUE ANALYSIS

22.18.3 PRODUCT PORTFOLIO

22.18.4 RECENT DEVELOPMENT

22.19 QUEST DIAGNOSTICS INCORPORATED

22.19.1 COMPANY SNAPSHOT

22.19.2 SWOT

22.19.3 REVENUE ANALYSIS

22.19.4 PRODUCT PORTFOLIO

22.19.5 RECENT DEVELOPMENT

22.2 THERMO FISHER SCIENTIFIC INC.

22.20.1 COMPANY SNAPSHOT

22.20.2 REVENUE ANALYSIS

22.20.3 PRODUCT PORTFOLIO

22.20.4 RECENT DEVELOPMENT

23 QUESTIONNAIRE

24 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 U.S. CHRONIC PANCREATITIS TESTING: BY BLOOD MARKERS (NO. OF PATIENTS, TYPE OF TESTS TAKEN DURING TREATMENT

TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER

TABLE 2 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 3 U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 6 U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 10 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 11 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 12 U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 14 U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 15 U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 17 U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 18 U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 19 U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 20 U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 21 U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 22 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 23 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 24 U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 25 U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 26 U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 27 U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 29 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 30 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 32 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 33 SOUTHERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 34 SOUTHERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 35 SOUTHERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 36 SOUTHERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 37 SOUTHERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 SOUTHERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 39 SOUTHERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 40 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 41 SOUTHERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 42 SOUTHERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 43 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 44 SOUTHERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 45 SOUTHERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 46 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 47 SOUTHERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 48 SOUTHERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 49 SOUTHERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 50 SOUTHERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 51 SOUTHERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 52 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 53 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 54 SOUTHERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 55 SOUTHERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 56 SOUTHERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 57 SOUTHERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 58 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 59 SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 60 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 FLORIDA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 FLORIDA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 FLORIDA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 FLORIDA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 65 FLORIDA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 FLORIDA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 67 FLORIDA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 68 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 69 FLORIDA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 70 FLORIDA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 71 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 72 FLORIDA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 73 FLORIDA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 74 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 75 FLORIDA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 76 FLORIDA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 77 FLORIDA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 78 FLORIDA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 79 FLORIDA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 80 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 81 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 82 FLORIDA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 83 FLORIDA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 FLORIDA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 FLORIDA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 86 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 87 FLORIDA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 88 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 89 TEXAS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 90 TEXAS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 91 TEXAS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 92 TEXAS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 TEXAS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 TEXAS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 TEXAS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 96 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 97 TEXAS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 98 TEXAS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 99 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 100 TEXAS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 101 TEXAS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 102 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 103 TEXAS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 104 TEXAS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 105 TEXAS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 106 TEXAS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 107 TEXAS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 108 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 109 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 110 TEXAS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 111 TEXAS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 112 TEXAS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 TEXAS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 TEXAS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 116 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 117 NORTH CAROLINA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 NORTH CAROLINA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 119 NORTH CAROLINA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 120 NORTH CAROLINA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 NORTH CAROLINA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 122 NORTH CAROLINA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 123 NORTH CAROLINA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 125 NORTH CAROLINA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 126 NORTH CAROLINA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 127 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 128 NORTH CAROLINA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 129 NORTH CAROLINA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 130 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 131 NORTH CAROLINA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 132 NORTH CAROLINA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 133 NORTH CAROLINA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 134 NORTH CAROLINA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 135 NORTH CAROLINA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 136 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 137 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 NORTH CAROLINA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 139 NORTH CAROLINA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 140 NORTH CAROLINA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 141 NORTH CAROLINA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 143 NORTH CAROLINA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 144 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 145 GEORGIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 146 GEORGIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 147 GEORGIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 148 GEORGIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 149 GEORGIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 GEORGIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 151 GEORGIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 152 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 153 GEORGIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 154 GEORGIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 155 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 156 GEORGIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 157 GEORGIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 158 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 159 GEORGIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 160 GEORGIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 161 GEORGIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 162 GEORGIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 163 GEORGIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 164 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 165 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 GEORGIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 167 GEORGIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 168 GEORGIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 169 GEORGIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 170 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 171 GEORGIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 172 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 173 VIRGINIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 VIRGINIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 VIRGINIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 176 VIRGINIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 177 VIRGINIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 VIRGINIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 179 VIRGINIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 180 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 181 VIRGINIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 182 VIRGINIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 183 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 184 VIRGINIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 185 VIRGINIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 186 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 187 VIRGINIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 188 VIRGINIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 189 VIRGINIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 190 VIRGINIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 191 VIRGINIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 192 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 193 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 194 VIRGINIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 195 VIRGINIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 196 VIRGINIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 VIRGINIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 198 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 199 VIRGINIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 200 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 201 TENNESSEE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 202 TENNESSEE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 203 TENNESSEE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 204 TENNESSEE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 205 TENNESSEE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 TENNESSEE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 TENNESSEE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 209 TENNESSEE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 210 TENNESSEE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 TENNESSEE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 212 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 213 TENNESSEE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 214 TENNESSEE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 215 TENNESSEE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 216 TENNESSEE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 217 TENNESSEE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 218 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 219 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 220 TENNESSEE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 221 TENNESSEE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 222 TENNESSEE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 223 TENNESSEE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 224 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 225 TENNESSEE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 226 REST OF SOUTHERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 227 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 228 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 229 WESTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 230 WESTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 231 WESTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 232 WESTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 233 WESTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 234 WESTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 235 WESTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 236 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 237 WESTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 238 WESTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 239 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 240 WESTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 WESTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 242 WESTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 243 WESTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 244 WESTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 245 WESTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 246 WESTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 247 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 248 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 249 WESTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 250 WESTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 251 WESTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 252 WESTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 253 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 254 WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 255 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 256 ILLINOIS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 257 ILLINOIS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 258 ILLINOIS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 259 ILLINOIS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 260 ILLINOIS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 ILLINOIS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 262 ILLINOIS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 263 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 264 ILLINOIS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 265 ILLINOIS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 266 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 267 ILLINOIS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 ILLINOIS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 270 ILLINOIS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 271 ILLINOIS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 272 ILLINOIS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 273 ILLINOIS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 274 ILLINOIS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 275 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 276 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 277 ILLINOIS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 278 ILLINOIS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 279 ILLINOIS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 280 ILLINOIS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 281 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 282 ILLINOIS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 283 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 284 OHIO IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 285 OHIO MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 286 OHIO ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 287 OHIO CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 288 OHIO BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 289 OHIO TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 290 OHIO BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 291 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 292 OHIO STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 293 OHIO STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 294 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 295 OHIO EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 296 OHIO NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 297 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 298 OHIO INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 299 OHIO PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 300 OHIO KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 301 OHIO CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 302 OHIO CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 303 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 304 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 305 OHIO SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 306 OHIO DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 307 OHIO PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 308 OHIO RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 309 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 310 OHIO PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 311 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 312 MICHIGAN IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 313 MICHIGAN MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 314 MICHIGAN ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 315 MICHIGAN CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 316 MICHIGAN BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 317 MICHIGAN TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 318 MICHIGAN BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 319 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 320 MICHIGAN STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 321 MICHIGAN STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 322 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 323 MICHIGAN EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 324 MICHIGAN NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 325 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 326 MICHIGAN INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 327 MICHIGAN PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 328 MICHIGAN KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 329 MICHIGAN CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 330 MICHIGAN CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 331 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 332 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 333 MICHIGAN SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 334 MICHIGAN DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 335 MICHIGAN PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 336 MICHIGAN RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 337 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 338 MICHIGAN PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 339 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 340 INDIANA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 341 INDIANA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 342 INDIANA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 343 INDIANA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 344 INDIANA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 345 INDIANA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 346 INDIANA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 347 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 348 INDIANA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 349 INDIANA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 350 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 351 INDIANA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 352 INDIANA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 353 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 354 INDIANA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 355 INDIANA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 356 INDIANA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 357 INDIANA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 358 INDIANA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 359 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 360 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 361 INDIANA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 362 INDIANA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 363 INDIANA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 364 INDIANA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 365 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 366 INDIANA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 367 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 368 MISSOURI IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 369 MISSOURI MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 MISSOURI ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 371 MISSOURI CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 372 MISSOURI BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 373 MISSOURI TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 374 MISSOURI BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 375 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 376 MISSOURI STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 377 MISSOURI STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 378 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 379 MISSOURI EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 380 MISSOURI NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 381 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 382 MISSOURI INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 383 MISSOURI PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 384 MISSOURI KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 385 MISSOURI CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 386 MISSOURI CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 387 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 388 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 389 MISSOURI SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 390 MISSOURI DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 391 MISSOURI PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 392 MISSOURI RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 393 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 394 MISSOURI PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 395 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 396 MINNESOTA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 397 MINNESOTA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 398 MINNESOTA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 399 MINNESOTA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 400 MINNESOTA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 401 MINNESOTA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 402 MINNESOTA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 403 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 404 MINNESOTA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 405 MINNESOTA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 406 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 407 MINNESOTA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 408 MINNESOTA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 409 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 410 MINNESOTA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 411 MINNESOTA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 412 MINNESOTA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 413 MINNESOTA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 414 MINNESOTA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 415 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 416 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 417 MINNESOTA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 418 MINNESOTA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 419 MINNESOTA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 420 MINNESOTA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 421 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 422 MINNESOTA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 423 REST OF WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 424 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 425 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 426 MID-WESTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 427 MID-WESTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 428 MID-WESTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 429 MID-WESTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 430 MID-WESTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 431 MID-WESTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 432 MID-WESTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 433 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 434 MID-WESTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 435 MID-WESTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 436 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 437 MID-WESTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 438 MID-WESTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 439 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 440 MID-WESTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 441 MID-WESTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 442 MID-WESTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 443 MID-WESTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 444 MID-WESTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 445 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 446 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 447 MID-WESTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 448 MID-WESTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 449 MID-WESTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 450 MID-WESTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 451 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 452 MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 453 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 454 CALIFORNIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 455 CALIFORNIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 456 CALIFORNIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 457 CALIFORNIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 458 CALIFORNIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 459 CALIFORNIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 460 CALIFORNIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 461 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 462 CALIFORNIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 463 CALIFORNIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 464 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 465 CALIFORNIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 466 CALIFORNIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 467 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 468 CALIFORNIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 469 CALIFORNIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 470 CALIFORNIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 471 CALIFORNIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 472 CALIFORNIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 473 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 474 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 475 CALIFORNIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 476 CALIFORNIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 477 CALIFORNIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 478 CALIFORNIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 479 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 480 CALIFORNIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 481 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 482 WASHINGTON IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 483 WASHINGTON MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 484 WASHINGTON ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 485 WASHINGTON CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 486 WASHINGTON BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 487 WASHINGTON TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 488 WASHINGTON BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 489 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 490 WASHINGTON STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 491 WASHINGTON STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 492 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 493 WASHINGTON EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 494 WASHINGTON NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 495 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 496 WASHINGTON INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 497 WASHINGTON PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 498 WASHINGTON KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 499 WASHINGTON CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 500 WASHINGTON CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 501 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 502 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 503 WASHINGTON SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 504 WASHINGTON DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 505 WASHINGTON PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 506 WASHINGTON RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 507 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 508 WASHINGTON PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 509 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 510 ARIZONA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 511 ARIZONA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 512 ARIZONA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 513 ARIZONA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 514 ARIZONA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 515 ARIZONA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 516 ARIZONA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 517 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 518 ARIZONA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 519 ARIZONA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 520 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 521 ARIZONA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 522 ARIZONA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 523 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 524 ARIZONA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 525 ARIZONA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 526 ARIZONA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 527 ARIZONA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 528 ARIZONA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 529 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 530 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 531 ARIZONA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 532 ARIZONA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 533 ARIZONA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 534 ARIZONA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 535 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 536 ARIZONA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 537 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 538 COLORADO IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 539 COLORADO MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 540 COLORADO ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 541 COLORADO CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 542 COLORADO BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 543 COLORADO TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 544 COLORADO BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 545 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 546 COLORADO STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 547 COLORADO STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 548 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 549 COLORADO EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 550 COLORADO NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 551 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 552 COLORADO INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 553 COLORADO PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 554 COLORADO KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 555 COLORADO CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 556 COLORADO CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 557 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 558 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 559 COLORADO SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 560 COLORADO DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 561 COLORADO PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 562 COLORADO RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 563 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 564 COLORADO PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 565 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 566 OREGON IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 567 OREGON MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 568 OREGON ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 569 OREGON CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 570 OREGON BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 571 OREGON TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 572 OREGON BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 573 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 574 OREGON STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 575 OREGON STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 576 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 577 OREGON EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 578 OREGON NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 579 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 580 OREGON INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 581 OREGON PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 582 OREGON KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 583 OREGON CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 584 OREGON CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 585 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 586 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 587 OREGON SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 588 OREGON DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 589 OREGON PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 590 OREGON RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 591 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 592 OREGON PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 593 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 594 NEVADA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 595 NEVADA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 596 NEVADA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 597 NEVADA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 598 NEVADA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 599 NEVADA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 600 NEVADA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 601 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 602 NEVADA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 603 NEVADA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 604 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 605 NEVADA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 606 NEVADA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 607 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 608 NEVADA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 609 NEVADA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 610 NEVADA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 611 NEVADA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 612 NEVADA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 613 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 614 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 615 NEVADA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 616 NEVADA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 617 NEVADA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 618 NEVADA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 619 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 620 NEVADA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 621 REST OF MID-WESTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 622 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 623 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 624 NORTHEASTERN U.S. IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 625 NORTHEASTERN U.S. MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 626 NORTHEASTERN U.S. ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 627 NORTHEASTERN U.S. CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 628 NORTHEASTERN U.S. BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 629 NORTHEASTERN U.S. TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 630 NORTHEASTERN U.S. BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 631 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 632 NORTHEASTERN U.S. STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 633 NORTHEASTERN U.S. STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 634 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 635 NORTHEASTERN U.S. EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 636 NORTHEASTERN U.S. NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 637 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 638 NORTHEASTERN U.S. INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 639 NORTHEASTERN U.S. PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 640 NORTHEASTERN U.S. KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 641 NORTHEASTERN U.S. CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 642 NORTHEASTERN U.S. CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 643 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 644 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 645 NORTHEASTERN U.S. SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 646 NORTHEASTERN U.S. DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 647 NORTHEASTERN U.S. PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 648 NORTHEASTERN U.S. RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 649 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 650 NORTHEASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 651 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 652 NEW YORK IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 653 NEW YORK MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 654 NEW YORK ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 655 NEW YORK CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 656 NEW YORK BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 657 NEW YORK TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 658 NEW YORK BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 659 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 660 NEW YORK STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 661 NEW YORK STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 662 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 663 NEW YORK EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 664 NEW YORK NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 665 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 666 NEW YORK INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 667 NEW YORK PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 668 NEW YORK KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 669 NEW YORK CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 670 NEW YORK CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 671 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 672 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 673 NEW YORK SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 674 NEW YORK DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 675 NEW YORK PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 676 NEW YORK RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 677 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 678 NEW YORK PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 679 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 680 PENNSYLVANIA IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 681 PENNSYLVANIA MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 682 PENNSYLVANIA ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 683 PENNSYLVANIA CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 684 PENNSYLVANIA BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 685 PENNSYLVANIA TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 686 PENNSYLVANIA BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 687 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 688 PENNSYLVANIA STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 689 PENNSYLVANIA STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 690 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 691 PENNSYLVANIA EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 692 PENNSYLVANIA NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 693 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 694 PENNSYLVANIA INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 695 PENNSYLVANIA PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 696 PENNSYLVANIA KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 697 PENNSYLVANIA CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 698 PENNSYLVANIA CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 699 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 700 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 701 PENNSYLVANIA SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 702 PENNSYLVANIA DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 703 PENNSYLVANIA PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 704 PENNSYLVANIA RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 705 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 706 PENNSYLVANIA PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 707 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 708 NEW JERSEY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 709 NEW JERSEY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 710 NEW JERSEY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 711 NEW JERSEY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 712 NEW JERSEY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 713 NEW JERSEY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 714 NEW JERSEY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 715 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 716 NEW JERSEY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 717 NEW JERSEY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 718 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 719 NEW JERSEY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 720 NEW JERSEY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 721 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 722 NEW JERSEY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 723 NEW JERSEY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 724 NEW JERSEY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 725 NEW JERSEY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 726 NEW JERSEY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 727 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 728 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 729 NEW JERSEY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 730 NEW JERSEY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 731 NEW JERSEY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 732 NEW JERSEY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 733 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 734 NEW JERSEY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 735 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 736 MASSACHUSETTS IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 737 MASSACHUSETTS MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 738 MASSACHUSETTS ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 739 MASSACHUSETTS CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 740 MASSACHUSETTS BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 741 MASSACHUSETTS TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 742 MASSACHUSETTS BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 743 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 744 MASSACHUSETTS STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 745 MASSACHUSETTS STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 746 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 747 MASSACHUSETTS EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 748 MASSACHUSETTS NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 749 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 750 MASSACHUSETTS INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 751 MASSACHUSETTS PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 752 MASSACHUSETTS KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 753 MASSACHUSETTS CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 754 MASSACHUSETTS CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 755 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 756 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 757 MASSACHUSETTS SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 758 MASSACHUSETTS DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 759 MASSACHUSETTS PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 760 MASSACHUSETTS RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 761 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 762 MASSACHUSETTS PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 763 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 764 MARYLAND IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 765 MARYLAND MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 766 MARYLAND ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 767 MARYLAND CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 768 MARYLAND BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 769 MARYLAND TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 770 MARYLAND BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 771 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 772 MARYLAND STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 773 MARYLAND STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 774 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 775 MARYLAND EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 776 MARYLAND NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 777 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 778 MARYLAND INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 779 MARYLAND PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 780 MARYLAND KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 781 MARYLAND CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 782 MARYLAND CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 783 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 784 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 785 MARYLAND SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 786 MARYLAND DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 787 MARYLAND PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 788 MARYLAND RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 789 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 790 MARYLAND PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 791 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 792 CONNECTICUT IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 793 CONNECTICUT MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 794 CONNECTICUT ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 795 CONNECTICUT CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 796 CONNECTICUT BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 797 CONNECTICUT TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 798 CONNECTICUT BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 799 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 800 CONNECTICUT STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 801 CONNECTICUT STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 802 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 803 CONNECTICUT EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 804 CONNECTICUT NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 805 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 806 CONNECTICUT INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 807 CONNECTICUT PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 808 CONNECTICUT KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 809 CONNECTICUT CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 810 CONNECTICUT CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 811 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 812 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 813 CONNECTICUT SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 814 CONNECTICUT DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 815 CONNECTICUT PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 816 CONNECTICUT RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 817 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 818 CONNECTICUT PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 819 REST OF NORTH-EASTERN U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Abbildungsverzeichnis

FIGURE 1 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: U.S. VS REGIONAL MARKET ANALYSIS

FIGURE 5 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 10 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 11 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 AND 2030

FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. PANCREATIC CANCER DIAGNOSTICS MARKET

FIGURE 13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022

FIGURE 18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)

FIGURE 19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)

FIGURE 20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE

FIGURE 21 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022

FIGURE 22 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)

FIGURE 23 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030)

FIGURE 24 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE

FIGURE 25 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022

FIGURE 26 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 27 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 28 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 29 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022

FIGURE 30 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 31 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 32 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 33 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022

FIGURE 34 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 35 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 36 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 37 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 38 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 39 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 40 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 41 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 42 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 43 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 44 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 45 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The U.S. Pancreatic Cancer Diagnostics Market is projected to grow at a CAGR of 8.3% during the forecast period by 2030.

Which market segments are covered in this report?

The U.S. Pancreatic Cancer Diagnostics Market is segmented on the basis of test type, cancer stages, tumor type, product, application, technology, end user, and distribution channel.

Who are the major players operating in the market?

The major players in the U.S. Pancreatic Cancer Diagnostics Market are Agilent Technologies, Inc., BD, Biological Dynamics, CANON MEDICAL SYSTEMS CORPORATION, ClearNote Health, CTK Biotech, Inc., Danaher., Exact Sciences Corporation, F. Hoffman- La Roche Ltd, etc.

Which countries data are covered in the report?

The countries covered in the U.S. Pancreatic Cancer Diagnostics Market are Southern U.S., Western U.S., Mid-Western U.S., and North-Eastern U.S..

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Branchentrends und Prognose bis 2030

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Branchentrends und Prognose bis 2030

Us Pancreatic Cancer Diagnostics Market

CAGR : 8.30 %

Marktanalyse und Einblicke zur Diagnostik von Bauchspeicheldrüsenkrebs in den USA

Marktdynamik für Bauchspeicheldrüsenkrebsdiagnostik in den USA

Auswirkungen von COVID-19 auf den US-Markt für Bauchspeicheldrüsenkrebsdiagnostik

Umfang des US-Marktes für Bauchspeicheldrüsenkrebsdiagnostik

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Länderanalyse/Einblicke

Wettbewerbsumfeld und Analyse der Marktanteile für Bauchspeicheldrüsenkrebsdiagnostik in den USA

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Branchentrends und Prognose bis 2030

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Branchentrends und Prognose bis 2030

Us Pancreatic Cancer Diagnostics Market

CAGR : 8.30 %

Marktanalyse und Einblicke zur Diagnostik von Bauchspeicheldrüsenkrebs in den USA

Marktdynamik für Bauchspeicheldrüsenkrebsdiagnostik in den USA

Auswirkungen von COVID-19 auf den US-Markt für Bauchspeicheldrüsenkrebsdiagnostik

Umfang des US-Marktes für Bauchspeicheldrüsenkrebsdiagnostik

US-Markt für Bauchspeicheldrüsenkrebsdiagnostik – Länderanalyse/Einblicke

Wettbewerbsumfeld und Analyse der Marktanteile für Bauchspeicheldrüsenkrebsdiagnostik in den USA

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen